| Revenue Growth | Filspari $200.2M (up 120% YoY); Thiola/Buphenyl $20M; Total revenue $224.6M. |
|---|---|
| Mgmt Confidence | High confidence in $3B target; CEO transition described as 'position of strength'. |
| Demand Visibility | 1,932 new patient start forms in Q3 across IgAN and FSGS. |
| Order Book | Specialty pharmacy inventory increased $8M above historical levels in Q3. |
| Margin Trends | Gross-to-net discounts expected in mid-20% range for full year. |
| Op. Leverage | R&D and SG&A expenses totaled $168.7M; scaling with FSGS launch. |
| Vol vs Price | Growth driven by new patient starts and FSGS indication expansion. |
| Segment Growth | FSGS launch showing strong demand; IgAN seeing 'small decrease' in starts. |
| New Clients | 40% of FSGS prescribers were new to Filspari this quarter. |
| Capex & Debt | $471.8M cash; $112.5M upfront payment for Everest licensing agreement. |
| Regulatory | US IND for sparsentan-alternative (Ceborebrutinib) planned by year-end 2026. |
| Commentary | Emphasized Filspari as 'foundational kidney-targeted therapy' complementary to B-cell inhibitors. |
| New Launches | FSGS indication launched; Sparlight Phase 4 study initiating late 2026. |
Growth
Total revenue $224.6M; Filspari net sales $200.2M, up 120% year-over-year.
Outlook
Targeting $3 billion in annual Filspari sales by 2033; HCU top-line results 2H 2027.
Risks
Management pivoted to qualitative 'dynamism' language when pressed on sequential IgAN patient start form declines.
The company's earnings call, NASDAQ: TVTX, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Travere Therapeutics, Inc.: key numbers
- Share price
- $49.70Close, Nov 16
- Market cap
- $4.77B
- Shares outstanding
- 95.99MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Travere Therapeutics, Inc.
All →Travere Therapeutics Financial Results
Travere Therapeutics reported Q3 2026 financial results, highlighted by $200.2 million in FILSPARI net product sales, representing 120% year-over-year growth. The company is advancing its Phase 3 HARMONY study of pegtibatinase with topline results expected in the second half of 2027 and plans to submit an IND for civorebrutinib by year-end.
“Strong execution across our business drove another quarter of significant growth, with FILSPARI net product sales of $200 million for the quarter as we continued to expand our reach in IgAN and FSGS.”
Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics
“As I prepare to transition leadership to Bradley Campbell in December, I have never been more confident in Travere’s future, supported by an exceptional team, an expanding pipeline and a shared commitment to delivering hope to patients.”
Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics
Travere Therapeutics CEO Eric M. Dube Sells $13.1M of Stock
Eric M. Dube, CEO, sold 243,735 shares of Travere Therapeutics, Inc. at $52.97 to $55.02 a share (average $53.82) in 3 transactions, worth $13.1M in total on Oct 15, 2026. Shares held after the trade: 432,886 (-15.3%).
- Value
- $13.1M
- Shares
- 243,735
- Average price
- $53.82
- Role
- CEO
- Holding change
- -15.3%
- Trade date
- Oct 15, 2026
Travere Therapeutics Leadership Change
Travere Therapeutics announced that Eric Dube, Ph.D., will step down as President, CEO, and Board member effective December 1, 2026. Bradley L. Campbell, former CEO of Amicus Therapeutics, has been appointed as his successor. Dr. Dube will remain as an Executive Advisor through February 15, 2027, to facilitate a smooth leadership transition.
- Counterparty
- Bradley L. Campbell